IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Intra-Cellular Therapies, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, Calif.--()--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Intra-Cellular Therapies, Inc. (“Intra-Cellular” or the “Company”) (Nasdaq: ITCI) concerning possible violations of federal securities laws.

If you purchased shares of Intra-Cellular and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

The investigation focuses on whether Intra-Cellular and certain of its officers and/or directors violated federal securities laws. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” On May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

Contacts

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com